<?xml version="1.0" encoding="UTF-8"?>
<p>In the in-vivo model, the studied oil was able to control the disease progression, which was shown in the statistically significant smaller (
 <italic>p</italic> &lt; 0.05) lesion size (
 <xref ref-type="fig" rid="molecules-25-05514-f003">Figure 3</xref>A) and parasite burden (
 <xref ref-type="fig" rid="molecules-25-05514-f003">Figure 3</xref>B) with respect to untreated animals. Compared with Glucantime
 <sup>Â®</sup> (GTM), a similar efficacy (
 <italic>p</italic> &gt; 0.05) was found for EO-ML, as shown for lesion size (
 <xref ref-type="fig" rid="molecules-25-05514-f003">Figure 3</xref>A) and parasite burden (
 <xref ref-type="fig" rid="molecules-25-05514-f003">Figure 3</xref>B). 
 <xref ref-type="fig" rid="molecules-25-05514-f003">Figure 3</xref>C shows the differences among cutaneous lesions for each group, which was represented by one animal selected at random.
</p>
